infirst Healthcare
London
About infirst Healthcare
infirst HEALTHCARE is a new consumer healthcare company focused on improving well established drugs with IP protected solutions for the OTC/Primary care markets which can be launched within 12-36 months. infirst is a spin-out from SEEK, a UK privately-owned drug discovery group which uses its intellectual property to create breakthrough medicines addressing major diseases, bringing radical improvements to human health. infirst is led by CEO, Manfred Scheske, who was previously President of GSK's US$3 billion European Consumer Healthcare business (including brands such as alli, Aquafresh, Beechams, Corsodyl, Lucozade, Niquitin, Panadol. Piriton, Poligrip, Ribena, Sensodyne, Solpadeine, Zantac and Zovirax) from 2004 to 2010 and also spent six years as President of GSK's Consumer Healthcare business in North America
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $39.2M
- Last round: Series Unknown (Mar 2017)
- Website: infirst.co.uk
- Phone: +44 (0) 20 7153 6571
Industries & Categories
Consumer, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/infirst-healthcare-130869 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.